UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10-QSB

     (Mark  One)

     [ X ] Quarterly report under Section 13 or 15(d) of the Securities Exchange
     Act  of  1934

     For  the  quarterly  period  ended  June 30, 2002

     [    ]  Transition  report  under  Section  13  or  15(d) of the Securities
     Exchange  Act  of  1934

     For  the  transition  period  from  _________  to  _________

     Commission  File  No.  0-27039

                                 PROTEO, INC.
                 (Name of Small Business Issuer in Its Charter)

          NEVADA                                      88-0292249
(State or Other Jurisdiction of                     (IRS Employer
Incorporation or Organization)                 Identification Number)

                         2775 MESA VERDE EAST, F#101
                        COSTA MESA, CALIFORNIA, 92626
              (Address of Principal Executive Offices) (Zip Code)

                              (949) 979-7074
                       (Issuer's Telephone Number)

           SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
                                     (None)

           SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
                         Common Stock, par value $0.0001
                                (Title of Class)

     Check  whether  the  issuer  (1)  filed all reports required to be filed by
Section  13  or 15(d) of the Exchange Act during the past 12 months (or for such
shorter  period  that the registrant was required to file such reports); and (2)
has  been  subject  to  such  filing  requirements  for  the  past  90  days.

     Yes  [ X ]    No [   ]


     Indicate  the number of shares outstanding of each of the issuer's class of
common  stock  as  of  the  latest  practicable  date:

   Title of each class of Common Stock         Outstanding as August 29, 2002
   ----------------------------------------- ----------------------------------
   Common  Stock,  $0.0001  par  value                  21,600,434



     Transitional  Small  Business  Disclosure  Format  (check  one):

Yes [   ]  No [ X ]

<PAGE>

INDEX

                                PROTEO, INC.

PART  I.  FINANCIAL  INFORMATION

Item  1.  Consolidated  Financial  Statements

          Unaudited  Condensed  Consolidated  Balance  Sheet  as
          of  June  30,  2002

          Unaudited Condensed Consolidated Statements of Operations and
          Comprehensive Loss for  the  Three-month and Six-month Periods
          Ended June 30, 2002 and 2001 and for the  Period  From  November  22,
          2000  (Inception)  Through  June  30,  2002

          Unaudited  Condensed  Consolidated  Statements  of  Cash Flows for the
          Six-month Periods  Ended  June 30, 2002 and 2001 and for the Period
          From November 22, 2000 (Inception)  Through  June  30,  2002

          Notes  to  Unaudited  Condensed  Consolidated  Financial  Statements

Item 2.   Management's  Discussion  and  Analysis  of  Financial  Condition and
          Results of Operations

PART  II.  OTHER  INFORMATION

Item  1.  Legal  Proceedings

Item  2.  Changes  in  Securities

Item  3.  Defaults  Upon  Senior  Securities

Item  4.  Submission  of  Matters  to  a  Vote  of  Security  Holders

Item  5.  Other  Information

Item  6.  Exhibits  and  Reports  on  Form  8-K

<PAGE>
ITEM  1.  FINANCIAL  STATEMENTS

                          PROTEO, INC. AND SUBSIDIARIES
         (A DEVELOPMENT STAGE COMPANY, FORMERLY TRIVANTAGE GROUP, INC.)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                  JUNE 30, 2002
                                    UNAUDITED

<TABLE>
<CAPTION>


                                     ASSETS
<S>                                             <C>
CURRENT ASSETS
Cash . . . . . . . . . . . . . . . . . . . . .  $   691,465
Prepaid expenses and other current assets. . .       61,924
                                                    753,389

PROPERTY AND EQUIPMENT . . . . . . . . . . . .      246,192

                                                $   999,581

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable and accrued liabilities . . .  $   122,967
Accrued licensing fees . . . . . . . . . . . .      155,000
                                                    277,967

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Preferred stock, par value $0.001 per share;
10,000,000 shares authorized; no shares issued
and outstanding. . . . . . . . . . . . . . . .            -
Common stock, par value $0.001 per share;
300,000,000 shares authorized; 21,600,434
shares issued and outstanding. . . . . . . . .       21,601
Additional paid-in capital . . . . . . . . . .    3,613,513
Stock subscriptions receivable . . . . . . . .   (1,676,324)
Accumulated other comprehensive income . . . .       47,627
Deficit accumulated during development stage .   (1,284,803)
                                                    721,614
                                                ------------

                                                $   999,581
</TABLE>

See accompanying  notes  to  these condensed consolidated financial statements.

<PAGE>

                          PROTEO, INC. AND SUBSIDIARIES
         (A DEVELOPMENT STAGE COMPANY, FORMERLY TRIVANTAGE GROUP, INC.)
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                             AND COMPREHENSIVE LOSS
     FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2002 AND 2001
   AND FOR THE PERIOD FROM NOVEMBER 22, 2000 (INCEPTION) THROUGH JUNE 30, 2002
                                    UNAUDITED

<TABLE>
<CAPTION>
                                                                                          NOVEMBER
                                                                                          22, 2000
                                           THREE-      THREE-                            (INCEPTION)
                                           MONTHS      MONTHS     SIX-MONTHS  SIX-MONTHS  THROUGH
                                         ENDED JUNE  ENDED JUNE   ENDED JUNE  ENDED JUNE   JUNE 30,
                                          30, 2002    30, 2001    30, 2002    30, 2001       2002
                                         ----------  ----------  ----------  ----------  ------------
<S>                                      <C>         <C>         <C>         <C>         <C>

REVENUES
                                        $        -   $       -    $      -    $      -   $         -
EXPENSES
General and Administrative. . . . . . .    622,416      58,759     762,797     134,433     1,121,731
Research and Development, net of grants     20,152      30,081      93,679      47,848       175,561
                                         ----------  ----------  ----------  ----------  ------------
                                           642,568      88,840     856,476     182,281     1,297,292

INTEREST INCOME . . . . . . . . . . . .      2,884           -       6,034           -        12,489
                                         ----------  ----------  ----------  ----------  ------------

NET LOSS. . . . . . . . . . . . . . . .   (639,684)    (88,840)   (850,442)   (182,281)   (1,284,803)

FOREIGN CURRENCY TRANSLATION
    ADJUSTMENTS . . . . . . . . . . . .     94,396      (5,137)     68,120      (9,068)       47,627
                                         ----------  ----------  ----------  ----------  ------------

COMPREHENSIVE LOSS. . . . . . . . . . .  $(545,288)  $ (93,977)  $(782,322)  $(191,349)  $(1,237,176)
                                         ==========  ==========  ==========  ==========  ============
BASIC AND DILUTED LOSS PER
COMMON SHARE. . . . . . . . . . . .  $   (0.03)  $   (0.01)  $   (0.04)  $   (0.02)
                                     ==========  ==========  ==========  ==========

WEIGHTED  AVERAGE  NUMBER  OF
COMMON  SHARES OUTSTANDING               21,239,000   7,410,000  20,766,000  7,390,000
                                     ==========  ==========  ==========  ==========

</TABLE>

See  accompanying  notes  to  these condensed consolidated financial statements.

<PAGE>

                          PROTEO, INC. AND SUBSIDIARIES
         (A DEVELOPMENT STAGE COMPANY, FORMERLY TRIVANTAGE GROUP, INC.)
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
             FOR SIX-MONTH PERIODS ENDED JUNE 30, 2002 AND 2001, AND
   FOR THE PERIOD FROM NOVEMBER 22, 2000 (INCEPTION) THROUGH DECEMBER 31, 2002
                                    UNAUDITED


<TABLE>
<CAPTION>


                                                                        NOVEMBER
                                                                        22, 2000
                                                                      (INCEPTION)
                                            SIX-MONTHS   SIX-MONTHS     THROUGH
                                            ENDED JUNE   ENDED JUNE     JUNE 30,
                                             30, 2002     30, 2001        2002
                                           -----------  -----------  ------------
<S>                                        <C>          <C>          <C>
CASH FLOWS FROM OPERATING
   ACTIVITIES
Net loss. . . . . . . . . . . . . . . . .  $ (850,442)  $ (182,281)  $(1,284,803)
Changes in operating assets and
     liabilities:
Prepaid expenses and other current
   assets . . . . . . . . . . . . . . . .      13,280      (20,464)      (58,262)
Accounts payable and accrued
   liabilities. . . . . . . . . . . . . .     (37,815)      26,133        53,058
Accrued licensing fees. . . . . . . . . .      55,000       50,000       155,000
                                           -----------  -----------  ------------
NET CASH USED IN OPERATING ACTIVITIES . .    (819,977)    (126,612)   (1,135,007)

CASH FLOWS FROM INVESTING
    ACTIVITIES
Acquisition of property and equipment . .     (75,181)     (94,792)     (199,074)
Cash of reorganized entity. . . . . . . .           -            -        27,638
                                           -----------  -----------  ------------
NET CASH USED IN INVESTING ACTIVITIES . .     (75,181)     (94,792)     (171,436)

CASH FLOWS FROM FINANCING
    ACTIVITIES
Proceeds from issuance of common stock. .           -      227,957     1,587,610
Proceeds for subscribed stock . . . . . .     357,871        4,800       362,671
                                           -----------  -----------  ------------
NET CASH PROVIDED BY FINANCING ACTIVITIES     357,871      232,757     1,950,281

FOREIGN CURRENCY
    TRANSLATION ADJUSTMENT. . . . . . . .      68,120       (9,068)       47,627
                                           -----------  -----------  ------------

NET (DECREASE) INCREASE IN
    CASH. . . . . . . . . . . . . . . . .    (469,167)       2,285       691,465
                                           -----------  -----------  ------------

CASH - beginning of period. . . . . . . .   1,160,632       57,388             -
                                           -----------  -----------  ------------

CASH - end of period. . . . . . . . . . .  $  691,465   $   59,673   $   691,465
                                           ===========  ===========  ============
</TABLE>

See  accompanying  notes  to  these condensed consolidated financial statements.

<PAGE>


                          PROTEO, INC. AND SUBSIDIARIES
         (A DEVELOPMENT STAGE COMPANY, FORMERLY TRIVANTAGE GROUP, INC.)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                  JUNE 30, 2002


1.  NATURE  OF  BUSINESS  AND  BASIS  OF  PRESENTATION

BASIS  OF  PRESENTATION

The  management of Proteo, Inc. ("Proteo" or the "Company") and its wholly owned
subsidiaries  Proteo  Marketing,  Inc.  and  Proteo  Biotech, AG, without audit,
prepared the condensed consolidated financial statements for the three-month and
six-month  periods ended June 30, 2002 and 2001 and for the period from November
22,  2000  (Inception)  through  June  30,  2002.  Due to the merger with Proteo
Marketing,  Inc.  (see  Note 2), the reported amounts are those of the surviving
corporation.  The  results of operations of Proteo (formerly known as TriVantage
Group,  Inc.)  previously  filed in prior years are not included herein.  In the
opinion  of  management,  all  adjustments  necessary  to  present  fairly,  in
accordance with accounting principles generally accepted in the United States of
America,  the  Company's financial position as of June 30, 2002, and the results
of  operations  and  cash  flows for the three-month and six-month periods ended
March  31,  2002  and 2001 and for the period from November 22, 2000 (Inception)
through  June  30, 2002 have been made.  Such adjustments consist only of normal
recurring  adjustments.

Certain  note  disclosures  normally included in our annual financial statements
prepared  in  accordance  with  accounting  principles generally accepted in the
United States of America have been condensed or omitted pursuant to instructions
for  Form  10-QSB.  The  accompanying unaudited condensed consolidated financial
statements  should  be read in conjunction with the audited financial statements
and  notes  thereto which are included in Proteo, Inc.'s Form 8-K filed with the
Securities  and  Exchange  Commission  on  August  1,  2002.

The  results  of operations for the three-month and six-month periods ended June
30,  2002  are  not necessarily indicative of the results to be expected for the
full  year.

NATURE  OF  BUSINESS

TriVantage Group, Inc. changed its name to Proteo, Inc. on January 11, 2002, and
currently  trades  its  common  stock  on the OTC Bulletin Board of the National
Association  of  Securities  Dealers  under  the  symbol  "PTEO".

Proteo Marketing, Inc. ("PMI") was incorporated in the State of Nevada and began
operations  on  November  22,  2000.  In  December  2000,  PMI  entered  into  a
reorganization  and stock exchange agreement with Proteo Biotech AG, ("PBAG"), a
German corporation, incorporated in Kiel, Germany. As a result, PBAG is a wholly
owned subsidiary of PMI.  On April 25, 2002, PMI completed a reverse merger with
the  Company  (see  Note  2).


<PAGE>

1.  NATURE  OF  BUSINESS  AND  BASIS  OF  PRESENTATION  (continued)

NATURE  OF  BUSINESS  (continued)

The  Company  and  its  subsidiary  intend  to develop, manufacture, promote and
market pharmaceuticals and other biotech products. The Company is focused on the
development  of  pharmaceuticals  based on the human protein Elafin. Elafin is a
human  protein  that  naturally occurs in human skin, lungs, and mammary glands.
The  Company  believes  Elafin  may  be  useful  in  the  treatment  of  cardiac
infarction,  serious injuries caused by accidents, post surgery damage to tissue
and  complications  resulting  from  organ  transplantations.

Since  its inception, the Company has primarily been engaged in the research and
development of its proprietary product Elafin. Once the research and development
phase  is complete, the Company will begin to manufacture and obtain the various
governmental  regulatory  approvals for the marketing of Elafin.  The Company is
in  the development stage and has not generated revenues from any product sales.
The  Company  believes that none of its planned products will produce sufficient
revenues  in  the  near  future.  As a result, the Company plans to identify and
develop  other  potential  products.  There are no assurances, however, that the
Company will be able to produce such products, or if produced, that they will be
accepted  in  the  marketplace.

DEVELOPMENT  STAGE  AND  GOING  CONCERN

The  Company  has  been  in  the  development stage since it began operations on
November  22, 2000, and has not generated any revenues from operations and there
is  no  assurance  of  any  future  revenues.

The  Company will require substantial additional funding for continuing research
and  development, obtaining regulatory approval and for the commercialization of
its  product.  There can be no assurance that the Company will be able to obtain
sufficient  additional funds when needed, or that such funds, if available, will
be  obtainable  on  terms  satisfactory  to  the  Company.

Management  has  taken  action  to  address  these  matters.  They  include:

-     Retention  of  experienced  management personnel with particular skills in
      the  commercialization  of  such  products.
-     Attainment  of  technology  to  develop  additional  biotech  products.
-     Raising  additional  funds through the sale of debt and equity securities.


<PAGE>
1.  NATURE  OF  BUSINESS  AND  BASIS  OF  PRESENTATION  (continued)

DEVELOPMENT  STAGE  AND  GOING  CONCERN  (continued)

The Company's products, to the extent they may be deemed drugs or biologics, are
governed  by  the  Federal  Food,  Drug and Cosmetics Act and the regulations of
State  and  various  foreign  government  agencies.  The  Company's  proposed
pharmaceutical  products to be used with humans are subject to certain clearance
procedures  administered  by  the  above  regulatory  agencies.  There can be no
assurance  that  the  Company  will receive the regulatory approvals required to
market  its  proposed products elsewhere or that the regulatory authorities will
review  the  product  within  the  average  period  of  time.

Management  plans  to  obtain  revenues  from  product  sales,  but  there is no
commitment  by  any persons for purchase of any of the proposed products. In the
absence  of  significant  sales  and  profits,  the  Company  may  seek to raise
additional funds to meet its working capital requirements through the additional
sales of debt and equity securities. There is no assurance that the Company will
be  able  to obtain sufficient additional funds when needed, or that such funds,
if  available,  will  be  obtainable  on  terms  satisfactory  to  the  Company.

These circumstances, among others, raise concerns about the Company's ability to
continue  as a going concern. The accompanying consolidated financial statements
do  not  include  any  adjustments  that  might  result from the outcome of this
uncertainty.

RECENT  ACCOUNTING  PRONOUNCEMENTS

Recent accounting pronouncements discussed in the Notes to the December 31, 2001
and  2000 consolidated financial statements filed previously with the Securities
and  Exchange  Commission  in  Form  8-K that were required to be adopted in the
quarter  ended  June 30, 2002 did not have a significant impact on the Company's
financial  statements.

Statement  of  Financial  Accounting  Standards  ("SFAS") No. 145 rescinds three
existing pronouncements (relating to the intangible assets of motor carriers and
certain  debt extinguishments), amends SFAS No. 13, "Accounting for Leases", and
makes  technical corrections that are not substantive in nature to several other
pronouncements.  The  amendment  of  SFAS  No.  13,  which  is  effective  for
transactions occurring after May 15, 2002, requires sale-leaseback accounting by
lessees  for  certain  lease  modifications  that  are  economically  similar to
sale-leaseback  transactions.  SFAS  No.  145 did not have a material affect the
accompanying  2002 financial statements, and is not presently expected to have a
significant  impact  on  the  Company's  future  financial  statements.


<PAGE>

1.  NATURE  OF  BUSINESS  AND  BASIS  OF  PRESENTATION  (continued)

RECENT  ACCOUNTING  PRONOUNCEMENTS  (continued)

SFAS  No.  146,  "Accounting  for  Costs  Associated  with  Exit  or  Disposal
Activities," is effective for such activities initiated after December 31, 2002.
Activities of this type include restructurings (such as relocation of a business
and  fundamental  reorganizations  of a business itself), which may give rise to
costs  such  as  contract  cancellation  provisions,  employee  relocation,  and
one-time  termination  costs. SFAS No. 146 prohibits liability recognition based
solely  on  management's  intent,  and  requires that liabilities be measured at
estimated fair value.  Management has not determined the effect, if any, of SFAS
No.  146  on  the  Company's  future  financial  statements.


2.  REVERSE  MERGER

The  Company  entered  into  a  Shell  Acquisition  Agreement  (the "Acquisition
Agreement")  with  Proteo  Marketing,  Inc.  ("PMI").  In  accordance  with  the
Acquisition  Agreement,  PMI  originally  acquired 176,660,280 shares (1,313,922
post  split,  as described below) of the Company's common stock representing 90%
of  the  issued  and outstanding common stock of the Company. Upon completion of
the  Acquisition  Agreement,  the  Company completed a one for one-hundred-fifty
reverse  stock  split.  In  conjunction with the Acquisition Agreement, PMI paid
approximately  $500,000  to  SiteStar  Corporation,  the  former  parent  of the
Company.  Such  amount  was  recorded  as acquisition costs during the six-month
period  ended  June  30,  2002,  and  is  included in general and administrative
expenses in the accompanying condensed consolidated statements of operations and
comprehensive  loss.

Effective  April 25, 2002, the shareholders of PMI exchanged their shares of PMI
for  an  aggregate  of  20,286,512  shares  of  the  Company to effect a reverse
acquisition  (the  "Merger")  between  the PMI and Proteo, Inc. By virtue of the
Merger,  the  stockholders of the PMI acquired 20,286,512 shares of Proteo, Inc.
The  total  issued and outstanding shares of the combined entities subsequent to
the  Merger  was 21,600,434 shares. Since Proteo, Inc.'s previous and continuing
operations and balance sheet are insignificant, a pro forma consolidated balance
sheet  at  June  30,  2002  and  consolidated  statement  of  operations for the
six-month  periods  ended  June  30,  2002  and  2001  are  not  presented here.


<PAGE>

3.  STOCK  SUBSCRIPTIONS  RECEIVABLE  AND  OTHER  STOCK  ISSUES

During  the  six-month  period  ended  June  30,  2002,  the  Company  received
approximately $358,000 in connection with stock subscriptions receivable.  Other
than  the  reverse  merger  described in Note 2, there have been no issuances of
common  or  preferred stock during the six-month period ended June 30, 2002, nor
have  any  stock  options  been  granted.


4.  LOSS  PER  SHARE

The  Company computes net loss per common share using SFAS No. 128 "Earnings Per
Share."  Basic  loss  per common share is computed based on the weighted average
number  of shares outstanding for the period. Diluted loss per share is computed
by  dividing  net  loss  by the weighted average shares outstanding assuming all
dilutive  potential  common shares were issued. There were no dilutive potential
common  shares  at  June  30,  2002  and  2001.


5.  FOREIGN  CURRENCY  TRANSLATION

Assets  and  liabilities  of the Company's German operations are translated into
U.S. dollars at period-end exchange rates; equity transactions are translated at
historical  rates;  and  income  and  expense are translated at weighted average
exchange rates for the period.  Net exchange gains or losses resulting from such
translation  are  excluded  from  net earnings but are included in comprehensive
income  and  accumulated  in a separate component of stockholders' equity.  Such
amount  approximated  $48,000  at  June  30,  2002.


6.  SEGMENTS  OF  AN  ENTERPRISE  AND  RELATED  INFORMATION

The  Company  adopted SFAS No. 131, "Disclosures about Segments of an Enterprise
and  Related Information." SFAS No. 131 establishes standards for the way public
companies  report  information  about segments of their business in their annual
financial statements and requires them to report selected segment information in
their  quarterly  reports  issued  to shareholders. It also requires entity-wide
disclosures  about  the  products  and services an entity provides, the material
countries in which it holds assets and reports revenues and its major customers.
The  Company  generated no significant revenues during the six-months ended June
30,  2002.  All  fixed  assets  are  located  Germany.



<PAGE>

7.  GRANTS

The  German  state of Schleswig-Holstein granted Proteo Biotech AG approximately
790,000  Euros  for the research and development of the Company's pharmaceutical
product  Elafin. The grant originally covers the period from February 1, 2001 to
January  31, 2004 if certain milestones are reached by November 15 of each year,
with  a  possible  extension  as  defined  in  the  agreement.

The  grant  covers  49.99%  of  eligible  research and development costs and are
subject  to the Company's ability to cover the remaining 50.01% of the costs. An
additional  condition  of  the  grant is that the product is to be developed and
subsequently  produced  in  the  German  state  of  Schleswig-Holstein.

The  Company had qualified to receive approximately 322,000 and 153,000 Euros of
such  grant  in  2002  and 2001, respectively. Grant funds approximating 134,000
Euros have been received and recorded as a reduction of research and development
expenses  for  the  six-months  ended  June  30,  2002.  No grant funds had been
received  as  of June 30, 2001.  As of June 30, 2002, all milestones required by
the  grant  were  satisfied.

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS

CAUTIONARY  STATEMENTS:

This Quarterly Report on Form 10-QSB contains certain forward-looking statements
within  the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of  the  Securities  Exchange  Act  of  1934.  The  Company  intends  that  such
forward-looking  statements  be  subject  to  the  safe  harbors created by such
statutes.  The  forward-looking  statements included herein are based on current
expectations  that  involve a number of risks and uncertainties. Accordingly, to
the  extent  that  this  Quarterly  Report  contains  forward-looking statements
regarding  the financial condition, operating results, business prospects or any
other  aspect  of  the  Company,  please  be  advised  that the Company's actual
financial  condition,  operating  results  and  business  performance may differ
materially  from  that  projected or estimated by the Company in forward-looking
statements. The differences may be caused by a variety of factors, including but
not  limited  to  adverse  economic  conditions,  intense competition, including
intensification  of price competition and entry of new competitors and products,
adverse  federal,  state  and  local  government regulation, inadequate capital,
unexpected  costs  and  operating  deficits,  and  increases  in  general  and
administrative  costs,  and  other specific risks that may be alluded to in this
Quarterly  Report  or  in  other reports issued by the Company. In addition, the
business  and  operations  of  the Company are subject to substantial risks that
increase  the  uncertainty  inherent  in  the  forward-looking  statements.  The
inclusion  of  forward looking statements in this Quarterly Report should not be
regarded  as  a  representation  by  the  Company  or  any other person that the
objectives  or  plans  of  the  Company  will  be  achieved.

The  Company  does  not  currently  generate  any  significant  revenue from its
operations  and  does  not  expect  to  report any significant revenue until the
successful  development  and marketing of  its  planned pharmaceutical and other
biotech  products.  Additionally,  after  the  launch  of the Company's service,
there  can be no assurance that the Company will generate positive cash flow and
there can be no assurances as to the level of  revenues,  if  any,  the  Company
may  actually  achieve  from  its  planned  operations.

Plan  of  Operations

The  Company intends to specialize in the research, development and marketing of
drugs  for inflammatory diseases with Elafin as its first project. The Company's
management  deems  Elafin  to  be  one of the most prospective substances in the
treatment  of  serious  tissue and muscle damage. Independently conducted animal
experiments  have  indicated  that  Elafin may have benefits in the treatment of
tissue  and muscle damage caused by insufficient oxygen supply and therefore may
be  useful in the treatment of heart attacks, serious injuries and in the course
of  organ  transplants.  Other  applications  have  yet  to  be  determined.


<PAGE>

The  Company  intends  to implement Elafin as a drug in the treatment of serious
tissue  and  muscle damage, e.g. due to traffic accidents and intends to achieve
governmental  approval  in  Europe first.  Currently, management assumes that it
will take at least five years to achieve first governmental approval for the use
of  Elafin  as  a drug in the treatment of serious tissue and muscle damage.  In
order  to  conduct  pre-clinical  and  clinical  trials,  the Company must first
complete  the  research  and  development  of an efficient production process in
accordance  with  GMP  (Good  Manufacturing  Practices)  standards.

The  Company's  success  will  depend  on  its  ability  to  implement efficient
production  process  in  accordance with GMP standards, to examine toxicology in
animal experiments, and to prove that Elafin is well tolerated by humans and its
efficiency  in  the  indicated  treatment.  There  can  be no assurance that the
Company  will  be  able  to develop feasible production procedures in accordance
with  GMP  standards,  or that Elafin will receive any governmental approval for
the  use  as  drug  in  any  of  the  intended  applications.

In  collaboration  with  a  non-affiliated  third party company, the Company has
identified  the yeast to be utilized in the production of Elafin and has ordered
the third party to develop efficient clones of such yeasts.  Simultaneously, the
Company  is  attempting  to  optimize  the  yeast expression systems to increase
efficient  production  of  such  yeast.   Also, the Company is in the process of
equipping  its  recently  rented  facilities  and  to  scale up its fermentation
facilities  to  be able to produce sufficient amounts of Elafin for its research
and  development. The Company's management intends to have animal experiments on
the  toxicology  as  needed  to  enter governmental approval procedures in 2003.

LIQUIDITY  AND  CAPITAL  RESOURCES

Since  Inception,  the  Company  has  raised a total of approximately $3,626,000
from the sale of 17,786,512 shares of common stock , of which,  5,085,487 shares
have  been  sold  at $0.40  per  share  under a stock subscription agreement  in
the amount  of  approximately $2,035,000 .  As of June 30, 2002, the Company has
received  approximately  $380,000  related  to the stock subscription agreement.

Additionally, the Company's wholly owned German subsidiary Proteo Biotech AG has
received  a  grant  from  the  German  State Schleswig-Holstein in the amount of
approximately  $700,000.  Such  grant  shall  cover  49.99% of related costs and
expenses  of research and development of the Company's Elafin project during the
period from 2001 to 2004 and will be offset against such costs and expenses. The
grant  will  depend  on  the Company's ability to cover 50.01% of such costs and
expenses,  and  from  the  achievement  of  milestones.  During  the  six months
period  ended  June 30, 2002, the Company has received approximately $120,000 of
the  grant  which  has  been netted against the related research and development
expenses.

The  Company's  cash  was  approximately  $690,000  as  of  June  30,  2002. The
increase  compared  to $59,673 as of June 30, 2001 is due to proceeds from stock
issuances  and  stock  subscriptions,  as well as the off set of expenses by the
grant  received.

<PAGE>

During  the  period ended June 30, 2002, the Company paid approximately $500,000
to Sitestar (the former parent of TriVantage Group, Inc.) in connection with the
reverse  merger.  The  Company recorded the payment of approximately $500,000 in
general  and  administrative  expenses  during  the  period ended June 30, 2002.


The  Management  of  the Company believes that the Company will not generate any
significant  revenues  in the next few years nor will it have sufficient cash to
fund  operations.  As a result, the Company's success will largely depend on its
ability to secure additional funding through the sale of its Common Stock and/or
the  sale of other debt securities. There can be no assurance, however, that the
Company  will be able to consummate debt or equity financing in a timely manner,
or  on  a  basis  favorable  to  the  Company,  at  all.

CAPITAL  EXPENDITURES

The  Company  intends  to  purchase  capital  equipment  over  the  next  twelve
months to meet the Company's research  and  development requirements.  The costs
are  estimated  to  total  approximately  $350,000.

<PAGE>

                                      PART II
                                  OTHER INFORMATION



Item 1.  Legal Proceedings

The  Company  may  from  time  to  time be involved in various claims, lawsuits,
disputes with third parties, actions involving allegations of discrimination, or
breach  of  contract  actions  incidental  to the operation of its business. The
Company is not currently involved in any such litigation which it believes could
have  a  materially  adverse  effect  on  its  financial condition or results of
operations.

Item 2.  Changes in Securities and Use of Proceeds

On  April  25,  2002,  pursuant  to an Agreement and Plan of Share Exchange, the
Company  issued  an  aggregate  of  20,286,512 shares of its common stock to the
shareholders  of  Proteo  Marketing, Inc. The shares were issued without general
solicitation  in  a  private  transaction  to  foreign  residents  pursuant  to
Regulation  S  of  the  Securities  Act  of  1933.

Item 3.  Defaults Upon Senior Securities

None.

Item 4.  Submission Of Matters To A Vote Of Security Holders

None.

Item 5.  Other Information

None.

Item 6.  Exhibits and Reports on Form 8-K

(a)          Exhibits

99.1  Certification  Pursuant  to  18  USC, Section 1350, as Adopted Pursuant to
Sections  302  and  906  of  the  Sarbanes-Oxley  Act  of  2002

99.2  Certification  Pursuant  to  18  USC, Section 1350, as Adopted Pursuant to
Sections  302  and  906  of  the  Sarbanes-Oxley  Act  of  2002


(b)          Reports  on  Form  8-K

On  August  1,  2002,  the Company filed an Amended Current Report on Form 8-K/A
providing financial statements to Current Report on Form 8-K previously filed on
May  6,  2002.

On July 12, 2002, the Company filed a Current Report on Form 8-K reporting a
change in  its  auditors  of  record.

On  May  6,  2002,  the Company filed a Current Report on Form 8-K reporting the
completion  of  its  Share  Exchange  with  Proteo  Marketing,  Inc.

On  April 5, 2002, Company filed a Current Report on form 8-K reporting a change
in  its  auditors  of  record.


<PAGE>
                          SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934. The
registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                              PROTEO, INC.

                              By /s/ Joerg Alte
                              ----------------------------------
                              Joerg Alte
                              Chief Executive Officer & Chief
                              Financial Officer


Dated: August 29, 2002